A review of erlotinib and its clinical use
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/14656566.7.2.177
Reference111 articles.
1. Cell Signaling by Receptor Tyrosine Kinases
2. The EGFR family and its ligands in human cancer
3. NEW EMBO MEMBERS' REVIEW: The ErbB signaling network: receptor heterodimerization in development and cancer
4. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification.
5. Prognostic Applications of the Epidermal Growth Factor Receptor and Its Ligand, Transforming Growth Factor-α
Cited by 80 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Harnessing nanotechnology for enhanced delivery of erlotinib: a dynamic duo in cancer treatment;Beni-Suef University Journal of Basic and Applied Sciences;2024-07-26
2. Synthesis, Anticancer Activity, and Docking Studies of Novel Hydroquinone-Chalcone-Pyrazoline Hybrid Derivatives;International Journal of Molecular Sciences;2024-07-02
3. Advances in erlotinib delivery systems: Addressing challenges and exploring opportunities in EGFR-targeted cancer therapies;Inorganic Chemistry Communications;2024-03
4. Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers;Breast Cancer: Targets and Therapy;2023-11
5. Review on EGFR-ERK1/2 signaling cascade: implications on cell proliferation in health and disease;Egyptian Pharmaceutical Journal;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3